Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLX101-Tx with or without lomustine for first recurrent glioblastoma
ACTRN12625000934448Phase 3Not yet recruiting
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Sep 2025
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 4
01
Overview
Phase 3, open-label trial of 4-iodophenylalanine I-131 and lomustine in glioblastoma (GBM) (3 arms), sponsored by Telix Pharmaceuticals Limited. Primary endpoints: Maximum tolerated dose of TLX101-Tx plus lomustine or TLX101-Tx monotherapy, Dose optimization and recommended phase III dose and 1 more. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
4-iodophenylalanine I-131lomustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ACTRN12625000934448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12625000934448.